Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Dec 31;10(1):24.
doi: 10.1186/1477-9560-10-24.

Treatment of venous thromboembolism - effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management

Bastian Hass  1 , Jayne Pooley, Adrian E Harrington, Andreas Clemens, Martin Feuring
Affiliations

Treatment of venous thromboembolism - effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management

Bastian Hass et al. Thromb J. .

Abstract

Effective treatment of venous thromboembolism (VTE) strikes a balance between prevention of recurrence and bleeding complications. The current standard of care is heparin followed by a vitamin K antagonist such as warfarin. However, this option is not without its limitations, as the anticoagulant effect of warfarin is associated with high inter- and intra-patient variability and patients must be regularly monitored to ensure that anticoagulation is within the narrow target therapeutic range. Several novel oral anticoagulant agents are in the advanced stages of development for VTE treatment, some of which are given after an initial period of heparin treatment, in line with current practice, while others switch from high to low doses after the initial phase of treatment. In this review we assess the critical considerations for treating VTE in light of emerging clinical data for new oral agents and discuss the merits of novel treatment regimens for patients who have experienced an episode of deep vein thrombosis or pulmonary embolism.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Rates of VTE recurrence in registry patients[3-5].
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest. 2008;133:454S–545S. doi: 10.1378/chest.08-0658. - DOI - PubMed
    1. Stein PD, Hull RD, Matta F, Yaekoub AY. Anticoagulant therapy for acute venous thromboembolism: what we think we know and what the data show for the timing of recurrent events. Clin Appl Thromb Hemost. 2009;15:609–612. doi: 10.1177/1076029609349500. - DOI - PubMed
    1. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med. 2000;160:769–774. doi: 10.1001/archinte.160.6.769. - DOI - PubMed
    1. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ. III: Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000;160:761–768. doi: 10.1001/archinte.160.6.761. - DOI - PubMed
    1. Prandoni P, Villalta S, Bagatella P, Rossi L, Marchiori A, Piccioli A. et al.The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica. 1997;82:423–428. - PubMed